Knee Osteoarthritis Therapy: Recent Advances in Intra-Articular Drug Delivery Systems
Luoyang Ma,Xiaoyan Zheng,Rui Lin,Antonia RuJia Sun,Jintong Song,Zhiqiang Ye,Dahong Liang,Min Zhang,Jia Tian,Xin Zhou,Liao Cui,Yuyu Liu,Yanzhi Liu
DOI: https://doi.org/10.2147/DDDT.S357386
2022-05-04
Abstract:Luoyang Ma, 1, 2 Xiaoyan Zheng, 1, 3 Rui Lin, 1 Antonia RuJia Sun, 4 Jintong Song, 1 Zhiqiang Ye, 1 Dahong Liang, 1 Min Zhang, 1 Jia Tian, 1 Xin Zhou, 2 Liao Cui, 1 Yuyu Liu, 1 Yanzhi Liu 1, 3, 5 1 Guangdong Provincial Key Laboratory for Research and Development of Natural Drug, School of Pharmacy, Guangdong Medical University, Zhanjiang City, Guangdong Province, 524023, People's Republic of China; 2 Marine Medical Research Institute of Zhanjiang, Zhanjiang City, Guangdong Province, 524023, People's Republic of China; 3 Zhanjiang Central Hospital, Guangdong Medical University, Zhanjiang city, Guangdong province, 524045, People's Republic of China; 4 Center for Translational Medicine Research and Development, Shenzhen Institute of Advanced Technology, Chinese Academy of Science, Shenzhen City, Guangdong Province, 518055, People's Republic of China; 5 Shenzhen Osteomore Biotechnology Co., Ltd., Shenzhen city, Guangdong Province, 518118, People's Republic of China Correspondence: Yanzhi Liu; Yuyu Liu, Tel +86-759-2388405 ; +86-759-2388588, Email ; Drug delivery for osteoarthritis (OA) treatment is a continuous challenge because of their poor bioavailability and rapid clearance in joints. Intra-articular (IA) drug delivery is a common strategy and its therapeutic effects depend mainly on the efficacy of the drug-delivery system used for OA therapy. Different types of IA drug-delivery systems, such as microspheres, nanoparticles, and hydrogels, have been rapidly developed over the past decade to improve their therapeutic effects. With the continuous advancement in OA mechanism research, new drugs targeting specific cell/signaling pathways in OA are rapidly evolving and effective drug delivery is critical for treating OA. In this review, recent advances in various IA drug-delivery systems for OA treatment, OA targeted strategies, and related signaling pathways in OA treatment are summarized and analyzed based on current publications. Keywords: osteoarthritis, knee, drug delivery, intra-articular Osteoarthritis (OA) is the most common degenerative joint disease that affects approximately more than 300 million people worldwide. 1,2 Knee OA(KOA) accounts for approximately 85% of all OA cases worldwide. 3 KOA represents a major public health challenge for the coming decades. The disease is ranked as the 10th largest cause of global years lived with disabilities, 4 and its prevalence has more than doubled in the last 10 years. 5,6 Medication management, hospitalizations, and joint surgery associated with OA treatment cost the healthcare system billions of dollars annually. 4,6 OA is a complex and multifactorial disease that involves various tissues lesion of the joint, including degenerative loss of articular cartilage, osteophyte formation, synovitis, subchondral bone remodeling and sclerosis, inflammation and fibrosis of the infrapatellar fat pad in the joints 7 (Figure 1) Traditionally, OA has been defined as an abnormal biomechanic-induced disorder causing extensive changes in joint homeostasis; however, it is not merely a passive degenerative disease of "wear-and-tear" as commonly described, but an active dynamic alteration arising from an imbalance between the repair and destruction of joint tissues with complex inflammatory and metabolic factors involved. 8,9 Over the last decade, OA has been increasingly recognized as a heterogeneous disease with the combined effects of aging, obesity, mechanical imbalance, gender, inflammation, metabolic imbalance, and genetic background. 10,11 The degradation of the articular cartilage is the central feature of KOA. 12 The local unbalanced biomechanical microenvironment and various biological factors in OA induce cartilage homeostasis dysregulation, resulting in collagen- and proteoglycan-rich extracellular matrix (ECM) degradation, articular surface fibrosis and erosion, cell death, matrix calcification, and vascular invasion. The progressive destruction of cartilage stimulated chondrocyte compensatory anabolism hypertrophy. Progressive destruction of cartilage stimulates chondrocytes to increase anabolism in the form of compensatory hypertrophy 13 and this process simultaneously produce matrix degradation products and pro-inflammatory mediators to accelerate the development of KOA. 14 With the further loss of cartilage and the exposure of subchondral bone, the increasing bone remodeling induces occurrence of osteophytosis, subchondral sclerosis, cyst formation, and abnormalities of bone contour in response to the rapid changes of the mechan -Abstract Truncated-